Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Regulation

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

Drug Control Governance: Regulatory Bodies and Their Impact

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In honor of those who served: The history of APhA and Federal pharmacy.

Journal of the American Pharmacists Association : JAPhA·2019

Same author

Good enough for America.

International journal of pharmaceutical compounding·2014

Same author

Comopounding in history: the road to wellville.

International journal of pharmaceutical compounding·2013

Same author

In the hands of your enemy.

International journal of pharmaceutical compounding·2013

Same author

Zada Mary cooper (1875-1961).

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2013

Same author

Lawrence Clayton Weaver 1924-2011: shouldn't we try?

Journal of the American Pharmacists Association : JAPhA·2012

Search research articles

Related Experiment Video

Updated: May 8, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Pharmaceutical legislation: an historical perspective.

Dennis B Worthen¹

¹Lloyd Scholar, Lloyd Library and Museum, Cincinnati, Ohio.

International Journal of Pharmaceutical Compounding

|August 27, 2013

Summary

This summary is machine-generated.

US pharmaceutical legislation evolved over 150 years, focusing on drug quality and safety. Key acts like the 1906 Pure Food and Drug Act and the 1938 Food, Drug and Cosmetic Act established crucial standards and consumer protections.

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Published on: August 1, 2018

Related Experiment Videos

Last Updated: May 8, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Published on: August 1, 2018

Area of Science:

Pharmaceutical Law
Drug Regulation
Public Health Policy

Background:

Pharmaceutical quality and consistency have been central to U.S. legislation for over a century.
Early laws like the Drug Importation Act of 1848 initiated regulatory efforts.
Public awareness of drug safety significantly increased with the 1906 Pure Food and Drug Act.

Purpose of the Study:

To describe the historical progression of pharmaceutical legislative initiatives in the United States.
To contextualize each legislative act within the prevailing pharmacy practice of its time.
To highlight the evolution of drug quality, safety, and consumer protection standards.

Main Methods:

Historical review of key U.S. pharmaceutical legislation.
Analysis of legislative impact on pharmacy practice and public health.
Contextualization of laws within their respective historical periods.

Main Results:

The Drug Importation Act of 1848 was an early, albeit limited, regulatory measure.
The 1906 Pure Food and Drug Act established the United States Pharmacopeia and National Formulary as quality standards.
The 1938 Food, Drug and Cosmetic Act addressed fraudulent claims and expanded regulatory oversight.

Conclusions:

U.S. pharmaceutical legislation demonstrates a progressive strengthening of drug quality and safety standards over time.
Each major legislative act built upon previous efforts, addressing identified shortcomings and expanding consumer protections.
The evolution of these laws reflects a growing societal demand for safe and effective pharmaceutical products.